Heart failure affects millions globally, yet treatment options remain limited for patients with reduced ejection fraction despite optimal medical therapy. The cardiac glycoside digitoxin, largely overshadowed by digoxin in clinical practice, may deserve renewed attention following compelling trial results.
The DIGIT-HF trial enrolled patients with advanced heart failure and reduced ejection fraction, randomizing them to digitoxin or placebo alongside standard guideline-directed therapy. Over 36 months of follow-up, digitoxin demonstrated an 18% relative risk reduction in the composite endpoint combining death from any cause and first hospitalization for worsening heart failure (hazard ratio 0.82). Notably, this benefit occurred without statistically significant increases in serious adverse events, addressing long-standing safety concerns about cardiac glycosides.
This finding represents a significant development in heart failure therapeutics, where new treatment options have been scarce despite the condition's devastating impact on quality of life and survival. Digitoxin's longer half-life compared to digoxin may offer pharmacokinetic advantages, particularly for patients with varying kidney function. However, the trial's design raises important questions about clinical implementation. While the composite endpoint showed benefit, neither all-cause mortality nor hospitalization alone reached statistical significance, suggesting the effect may be driven by one component more than the other. The heart failure community will need to weigh whether an 18% composite risk reduction justifies reintroducing a drug class many clinicians abandoned due to narrow therapeutic windows and potential toxicity concerns. Further subgroup analyses and real-world safety data will be crucial for determining digitoxin's role in contemporary heart failure management.